(VRDN) Viridian Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92790C1045

Monoclonal Antibody, IGF-1R, Autoimmune, Fc Receptor

Biotechnology
Market Cap in USD: 3,030m

IPO / Inception: 2014-06-18
12m vs SPY: 67.0%

EPS (Earnings per Share)

EPS CAGR: 25.46%
EPS Trend: 60.1%

Last SUE: 3.15
Qual. Beats: 2

Revenue

Rev. CAGR: 369.38%
Rev. Trend: 12.2%

Last SUE: 4.00
Qual. Beats: 1

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	61.4%
Value at Risk 5%th	93.9%
Relative Tail Risk	-6.95%

Reward TTM
Sharpe Ratio	1.53
Alpha	71.44
CAGR/Max DD	-0.03

Character TTM
Hurst Exponent	0.328
Beta	0.907
Beta Downside	0.677

Drawdowns 3y
Max DD	70.69%
Mean DD	46.93%
Median DD	50.16%

Description: VRDN Viridian Therapeutics January 15, 2026

Viridian Therapeutics (NASDAQ:VRDN) is a U.S. biotech focused on monoclonal-antibody therapies for rare, high-unmet-need conditions, chiefly thyroid eye disease (TED). Its lead assets are veligrotug (an IGF-1R antibody) and VRDN-003 (a half-life-extended IGF-1R antibody), both currently in Phase 3 trials for TED, and a pipeline of engineered anti-neonatal Fc receptor (FcRn) inhibitors (VRDN-006, VRDN-008) targeting broader autoimmune indications.

Key market data (as of the most recent filing): market capitalization ≈ $190 million, cash and equivalents of $85 million, giving an estimated runway of ~12 months at current burn rates. The TED market is projected to exceed $1 billion globally, driven by rising prevalence of Graves’ disease and limited approved therapies, which creates a favorable pricing environment for a successful product.

Sector drivers that materially affect VRDN’s outlook include the biotech industry’s average Phase 3 success rate (~30 % for antibody programs) and the current U.S. regulatory climate, where the FDA’s accelerated approval pathways for rare-disease treatments could shorten time-to-market if efficacy endpoints are met.

Given the concentration of risk in a single indication, a disconfirming scenario would be a missed primary endpoint in the Phase 3 trials, which would likely force a pivot to the FcRn program and materially depress valuation.

For a deeper, data-driven assessment of VRDN’s risk-adjusted upside, you might explore the analyst tools on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-302.0m TTM) > 0 and > 6% of Revenue (6% = 4.25m TTM)

FCFTA -0.57 (>2.0%) and ΔFCFTA -30.97pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 736.3% (prev 240.4k%; Δ -239.7kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.56 (>3.0%) and CFO -326.0m <= Net Income -302.0m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 11.28 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (81.8m) change vs 12m ago 23.13% (target <= -2.0% for YES)

Gross Margin 99.83% (prev -2048 %; Δ 2148 pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 10.49% (prev 0.04%; Δ 10.46pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -118.9 (EBITDA TTM -299.0m / Interest Expense TTM 2.52m) >= 6 (WARN >= 3)

Altman Z'' -21.17

(A) 0.90 = (Total Current Assets 571.9m - Total Current Liabilities 50.7m) / Total Assets 577.1m

(B) -2.11 = Retained Earnings (Balance) -1.22b / Total Assets 577.1m

warn (B) unusual magnitude: -2.11 — check mapping/units

(D) -16.41 = Book Value of Equity -1.22b / Total Liabilities 74.2m

Total Rating: -21.17 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 34.74

1. Piotroski 1.0pt

2. FCF Yield -12.73%

3. FCF Margin data missing

4. Debt/Equity 0.05

5. Debt/Ebitda 0.49

6. ROIC - WACC (= -67.55)%

7. RoE -52.65%

8. Rev. Trend 12.25%

9. EPS Trend 60.12%

What is the price of VRDN shares?

As of January 15, 2026, the stock is trading at USD 33.78 with a total of 1,561,350 shares traded.
Over the past week, the price has changed by +10.50%, over one month by +2.27%, over three months by +62.56% and over the past year by +100.36%.

Is VRDN a buy, sell or hold?

Viridian Therapeutics has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy VRDN.

Strong Buy: 9
Buy: 5
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the VRDN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	41.7	23.5%
Analysts Target Price	41.7	23.5%
ValueRay Target Price	36.3	7.4%

VRDN Fundamental Data Overview January 13, 2026

P/S = 42.8073
P/B = 9.648
Revenue TTM = 70.8m USD
EBIT TTM = -299.5m USD
EBITDA TTM = -299.0m USD
Long Term Debt = 20.9m USD (from longTermDebt, last quarter)
Short Term Debt = 730.0k USD (from shortTermDebt, last quarter)
Debt = 23.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -145.8m USD (from netDebt column, last quarter)
Enterprise Value = 2.56b USD (3.03b + Debt 23.8m - CCE 490.9m)
Interest Coverage Ratio = -118.9 (Ebit TTM -299.5m / Interest Expense TTM 2.52m)
EV/FCF = -7.85x (Enterprise Value 2.56b / FCF TTM -326.3m)
FCF Yield = -12.73% (FCF TTM -326.3m / Enterprise Value 2.56b)
FCF Margin = -461.0% (FCF TTM -326.3m / Revenue TTM 70.8m)
Net Margin = -426.6% (Net Income TTM -302.0m / Revenue TTM 70.8m)
Gross Margin = 99.83% ((Revenue TTM 70.8m - Cost of Revenue TTM 123.0k) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 100.0%)
Tobins Q-Ratio = 4.44 (Enterprise Value 2.56b / Total Assets 577.1m)
Interest Expense / Debt = 2.35% (Interest Expense 560.0k / Debt 23.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -236.6m (EBIT -299.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.28 (Total Current Assets 571.9m / Total Current Liabilities 50.7m)
Debt / Equity = 0.05 (Debt 23.8m / totalStockholderEquity, last quarter 503.0m)
Debt / EBITDA = 0.49 (negative EBITDA) (Net Debt -145.8m / EBITDA -299.0m)
Debt / FCF = 0.45 (negative FCF - burning cash) (Net Debt -145.8m / FCF TTM -326.3m)
Total Stockholder Equity = 573.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.77% (Net Income -302.0m / Total Assets 577.1m)
RoE = -52.65% (Net Income TTM -302.0m / Total Stockholder Equity 573.6m)
RoCE = -50.37% (EBIT -299.5m / Capital Employed (Equity 573.6m + L.T.Debt 20.9m))
RoIC = -58.35% (negative operating profit) (NOPAT -236.6m / Invested Capital 405.4m)
WACC = 9.20% (E(3.03b)/V(3.05b) * Re(9.26%) + D(23.8m)/V(3.05b) * Rd(2.35%) * (1-Tc(0.21)))
Discount Rate = 9.26% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 28.30%
Fair Price DCF = unknown (Cash Flow -326.3m)
EPS Correlation: 60.12 | EPS CAGR: 25.46% | SUE: 3.15 | # QB: 2
Revenue Correlation: 12.25 | Revenue CAGR: 369.4% | SUE: 4.0 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-1.10 | Chg30d=+0.030 | Revisions Net=-1 | Analysts=5
EPS next Year (2026-12-31): EPS=-3.54 | Chg30d=-0.028 | Revisions Net=-1 | Growth EPS=+0.2% | Growth Revenue=-1.1%

Additional Sources for VRDN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle